Possible Role of The Tumor Suppressor Gene Retinoblastoma (Rb1) In Human Brain Tumor Development

2007 ◽  
Vol 14 (3) ◽  
pp. 72-82 ◽  
Author(s):  
Mathivanan Jothi ◽  
Rohini Keshava ◽  
Mohan L Gope ◽  
Rajalakshmi Gope
Keyword(s):  
Brain Tumor ◽  
Tumor Suppressor ◽  
Human Brain ◽  
Tumor Suppressor Gene ◽  
Tumor Development ◽  
Suppressor Gene ◽  
Human Brain Tumor

scholarly journals A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development

Oncogene ◽  
2000 ◽  
Vol 19 (8) ◽  
pp. 1052-1058 ◽  
Author(s):  
D J Jerry ◽  
F S Kittrell ◽  
C Kuperwasser ◽  
R Laucirica ◽  
E S Dickinson ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Tumor Development ◽  
Suppressor Gene ◽  
Specific Model ◽  
P53 Tumor Suppressor ◽  
P53 Tumor Suppressor Gene

Critical Role of ABCG2 in ALA-Photodynamic Diagnosis and Therapy of Human Brain Tumor

2015 ◽  
pp. 197-216 ◽  
Author(s):  
Toshihisa Ishikawa ◽  
Yoshinaga Kajimoto ◽  
Yutaka Inoue ◽  
Yoji Ikegami ◽  
Toshihiko Kuroiwa
Keyword(s):  
Brain Tumor ◽  
Human Brain ◽  
Critical Role ◽  
Photodynamic Diagnosis ◽  
Human Brain Tumor ◽  
Diagnosis And Therapy

Role of the p16 tumor suppressor gene in cancer.

1998 ◽  
Vol 16 (3) ◽  
pp. 1197-1206 ◽  
Author(s):  
W H Liggett ◽  
D Sidransky
Keyword(s):  
Cell Cycle ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Human Cancer ◽  
Suppressor Gene ◽  
Premalignant Lesions ◽  
Early Event ◽  
Cyclin Dependent Kinase ◽  
Primary Tumors

Since its discovery as a CDKI (cyclin-dependent kinase inhibitor) in 1993, the tumor suppressor p16 (INK4A/MTS-1/CDKN2A) has gained widespread importance in cancer. The frequent mutations and deletions of p16 in human cancer cell lines first suggested an important role for p16 in carcinogenesis. This genetic evidence for a causal role was significantly strengthened by the observation that p16 was frequently inactivated in familial melanoma kindreds. Since then, a high frequency of p16 gene alterations were observed in many primary tumors. In human neoplasms, p16 is silenced in at least three ways: homozygous deletion, methylation of the promoter, and point mutation. The first two mechanisms comprise the majority of inactivation events in most primary tumors. Additionally, the loss of p16 may be an early event in cancer progression, because deletion of at least one copy is quite high in some premalignant lesions. p16 is a major target in carcinogenesis, rivaled in frequency only by the p53 tumor-suppressor gene. Its mechanism of action as a CDKI has been elegantly elucidated and involves binding to and inactivating the cyclin D-cyclin-dependent kinase 4 (or 6) complex, and thus renders the retinoblastoma protein inactive. This effect blocks the transcription of important cell-cycle regulatory proteins and results in cell-cycle arrest. Although p16 may be involved in cell senescence, the physiologic role of p16 is still unclear. Future work will focus on studies of the upstream events that lead to p16 expression and its mechanism of regulation, and perhaps lead to better therapeutic strategies that can improve the clinical course of many lethal cancers.

Sign in / Sign up

Export Citation Format

Share Document